Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK plc presented promising preliminary data on Arexvy vaccine for adults aged 18-49 at risk for lower respiratory tract disease. The vaccine aims to protect a wider range of adults from the serious effects of RSV.